tirzepatide pregnancy safety guidance Who Qualifies for Medical Weight Loss Treatment? Compounded Tirzepatide Weight Loss Fort
Description
Eli Lilly and Company owns the patent to manufacture Zepbound and Mounjaro
Weight loss effects vary by population, with clinical trials showing up to 21-22% mean weight loss in obesity trials (non-diabetes patients) and lower percentages in type 2 diabetes patients, depending on dose
You have to balance the benefits of maternal weight loss and blood sugar control against the unknown long-term effects on the infant
Manufactured by Eli Lilly , this injection acts as a dual GIP and GLP-1 receptor agonist meaning it targets two natural incretin hormones to enhance insulin secretion and control glucose levels
